In an older adult with myelodysplastic syndrome receiving azacitidine on day 5 who has had two episodes of loose stool, what is the most likely cause and how should it be treated?

Azacitidine-Related Diarrhea: Likely Drug Effect Requiring Symptomatic Management

In this MDS patient on day 5 of azacitidine cycle #5 with two episodes of loose stool, the most likely cause is azacitidine-induced diarrhea, which is a common adverse effect occurring in this patient population and should be managed with loperamide and oral hydration as uncomplicated diarrhea.

Most Likely Cause

Diarrhea is a well-established adverse effect of azacitidine therapy. According to the FDA label, diarrhea is among the most commonly occurring adverse reactions in MDS patients receiving azacitidine 1. In clinical trials, gastrointestinal adverse events including diarrhea were frequently reported in azacitidine recipients 2.

The timing (day 5 of cycle) and presentation (two loose stools) are consistent with chemotherapy-related diarrhea rather than more serious complications.

Treatment Approach

For Uncomplicated Diarrhea (Current Presentation)

Since this patient has only two episodes of loose stool without fever, severe cramping, vomiting, dehydration, or neutropenic complications, this qualifies as uncomplicated diarrhea 3.

Immediate management:

• Start loperamide 4 mg initially, then 2 mg after every loose stool (maximum 16 mg/day) 3
• Oral hydration to prevent dehydration
• Dietary modifications: eliminate lactose-containing products and high-osmolar supplements 3
• Instruct patient to record stool frequency and report warning signs 3

Critical Monitoring Points

Watch for progression to complicated diarrhea, which would require hospitalization and aggressive management 3:

• Fever (raises concern for neutropenic enterocolitis)
• Moderate to severe cramping
• Nausea and vomiting
• Signs of dehydration (dizziness on standing)
• Diminished performance status
• Bloody diarrhea

Special Considerations in Elderly MDS Patients

This population is particularly vulnerable. In elderly cancer patients receiving chemotherapy, 74% report diarrhea during treatment, and this frailer population is at higher risk for dehydration, electrolyte imbalance, renal decline, and malnutrition 3. Aggressive prevention of skin breakdown is essential if incontinence develops 3.

Important Caveats

Rule Out Serious Complications

While drug-induced diarrhea is most likely, remain vigilant for:

1. Ischemic colitis: Rare but serious complication reported with azacitidine, particularly in elderly patients. One case series reported 4,491 cases/100,000 person-years—much higher than general population rates 4. The combination of anemia and constipation from antiemetics (5-HT3 antagonists) may contribute 4.

2. Hemorrhagic enteritis: Case reports describe severe hemorrhagic enteritis with intestinal ulcers developing after multiple azacitidine cycles, with shortening intervals between administration and symptoms 5.

3. Neutropenic enterocolitis: If fever develops with neutropenia, consider fluoroquinolone or metronidazole antibiotics, stool cultures, and possible hospitalization 3.

When to Escalate Care

Hospitalize immediately if:

• Fever develops (especially with neutropenia)
• Bloody diarrhea appears
• Signs of sepsis, dehydration, or bleeding emerge
• Diarrhea persists despite loperamide 3

For hospitalized complicated cases, consider octreotide 100-150 μg three times daily, IV fluids and electrolytes, and broad-spectrum antibiotics 3.

Practical Algorithm

1. Assess severity: Two loose stools without alarm features = uncomplicated
2. Start loperamide: 4 mg now, then 2 mg after each loose stool (max 16 mg/day)
3. Hydrate orally and modify diet (no lactose)
4. Monitor closely: Daily stool count, temperature checks, hydration status
5. Continue azacitidine if diarrhea controlled (dose modifications rarely needed for uncomplicated diarrhea)
6. Escalate immediately if fever, bleeding, severe cramping, or dehydration develops

The key is recognizing that while azacitidine-induced diarrhea is common and manageable 6, elderly MDS patients require heightened vigilance for both dehydration complications and rare but serious gastrointestinal toxicities 4, 5.